These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24793304)

  • 41. [TRPV1 in neuropathic pain: from animal models to therapeutical prospects].
    Danigo A; Magy L; Demiot C
    Med Sci (Paris); 2013; 29(6-7):597-606. PubMed ID: 23859514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Isobolographic Analysis of Drug Combinations With Intrathecal BRL52537 (κ-Opioid Agonist), Pregabalin (Calcium Channel Modulator), AF 353 (P2X3 Receptor Antagonist), and A804598 (P2X7 Receptor Antagonist) in Neuropathic Rats.
    Jung YH; Kim YO; Han JH; Kim YC; Yoon MH
    Anesth Analg; 2017 Aug; 125(2):670-677. PubMed ID: 28277328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oxcarbazepine for neuropathic pain.
    Zhou M; Chen N; He L; Yang M; Zhu C; Wu F
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD007963. PubMed ID: 29199767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sodium channel blockers for neuropathic pain.
    Zuliani V; Rivara M; Fantini M; Costantino G
    Expert Opin Ther Pat; 2010 Jun; 20(6):755-79. PubMed ID: 20384535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cellular and molecular mechanisms driving neuropathic pain: recent advancements and challenges.
    Fernandes V; Sharma D; Vaidya S; P A S; Guan Y; Kalia K; Tiwari V
    Expert Opin Ther Targets; 2018 Feb; 22(2):131-142. PubMed ID: 29285962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Piromelatine exerts antinociceptive effect via melatonin, opioid, and 5HT1A receptors and hypnotic effect via melatonin receptors in a mouse model of neuropathic pain.
    Liu YY; Yin D; Chen L; Qu WM; Chen CR; Laudon M; Cheng NN; Urade Y; Huang ZL
    Psychopharmacology (Berl); 2014 Oct; 231(20):3973-85. PubMed ID: 24700387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination pharmacotherapy for the treatment of neuropathic pain in adults.
    Chaparro LE; Wiffen PJ; Moore RA; Gilron I
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD008943. PubMed ID: 22786518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain.
    McDonald T; Liang HA; Sanoja R; Gotter AL; Kuduk SD; Coleman PJ; Smith KM; Winrow CJ; Renger JJ
    J Neurogenet; 2016 Mar; 30(1):32-41. PubMed ID: 27276194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Experimental Drugs for Neuropathic Pain.
    Salat K; Gryzlo B; Kulig K
    Curr Neuropharmacol; 2018; 16(8):1193-1209. PubMed ID: 29745335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Challenges relating to the therapeutic management of neuropathic pain.
    Alcántara Montero A; González Curado A
    Rev Esp Anestesiol Reanim (Engl Ed); 2019 Oct; 66(8):452-453. PubMed ID: 31153594
    [No Abstract]   [Full Text] [Related]  

  • 51. The plasticity of the association between mu-opioid receptor and glutamate ionotropic receptor N in opioid analgesic tolerance and neuropathic pain.
    Sánchez-Blázquez P; Rodríguez-Muñoz M; Berrocoso E; Garzón J
    Eur J Pharmacol; 2013 Sep; 716(1-3):94-105. PubMed ID: 23499699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Research progress of mechanisms and drug therapy for neuropathic pain.
    Yan YY; Li CY; Zhou L; Ao LY; Fang WR; Li YM
    Life Sci; 2017 Dec; 190():68-77. PubMed ID: 28964813
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computer-Aided Drug Discovery (CADD) Approaches for the Management of Neuropathic Pain.
    Ramesh M; Muthuraman A
    Curr Top Med Chem; 2021; 21(32):2856-2868. PubMed ID: 34809547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The endocannabinoid system and neuropathic pain.
    Maldonado R; Baños JE; Cabañero D
    Pain; 2016 Feb; 157 Suppl 1():S23-S32. PubMed ID: 26785153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting cannabinoid agonists for inflammatory and neuropathic pain.
    Cheng Y; Hitchcock SA
    Expert Opin Investig Drugs; 2007 Jul; 16(7):951-65. PubMed ID: 17594182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Challenges in the development of novel treatment strategies for neuropathic pain.
    Ossipov MH; Porreca F
    NeuroRx; 2005 Oct; 2(4):650-61. PubMed ID: 16489372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strategies for measuring non-evoked pain in preclinical models of neuropathic pain: Systematic review.
    Huerta MÁ; Cisneros E; Alique M; Roza C
    Neurosci Biobehav Rev; 2024 Aug; 163():105761. PubMed ID: 38852847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microinjection of histamine and its H
    Salimi S; Tamaddonfard E
    Eur J Pharmacol; 2019 Aug; 857():172450. PubMed ID: 31202805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats.
    Hsieh GC; Pai M; Chandran P; Hooker BA; Zhu CZ; Salyers AK; Wensink EJ; Zhan C; Carroll WA; Dart MJ; Yao BB; Honore P; Meyer MD
    Br J Pharmacol; 2011 Jan; 162(2):428-40. PubMed ID: 20880025
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief.
    Moriconi A; Cunha TM; Souza GR; Lopes AH; Cunha FQ; Carneiro VL; Pinto LG; Brandolini L; Aramini A; Bizzarri C; Bianchini G; Beccari AR; Fanton M; Bruno A; Costantino G; Bertini R; Galliera E; Locati M; Ferreira SH; Teixeira MM; Allegretti M
    Proc Natl Acad Sci U S A; 2014 Nov; 111(47):16937-42. PubMed ID: 25385614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.